Microtubule-targeting agents in angiogenesis: where do we stand?

Drug Resist Updat. Feb-Apr 2006;9(1-2):74-86. doi: 10.1016/j.drup.2006.04.003. Epub 2006 May 22.

Abstract

Angiogenesis is a key event of tumor progression and metastasis and hence a target for cancer chemotherapy. Therapeutic strategies focused on angiogenesis include the discovery of new, targeted anti-angiogenic agents and the re-evaluation of conventional anti-cancer drugs. Here, we review the most recent studies investigating the molecular and cellular mechanisms responsible for the anti-angiogenic activity of microtubule-targeting agents (MTAs). These agents include some of the most widely used and effective antitumor drugs that are also among the most anti-angiogenic. In addition, we summarize the latest results of pre-clinical and clinical studies involving MTAs administered at low metronomic doses and in anti-angiogenic combination strategies. Finally, we discuss the future development of these agents, their clinical potential and their limitations.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / pharmacology*
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Drug Administration Schedule
  • Humans
  • Local Government
  • Microtubules / drug effects*
  • Models, Biological*
  • Molecular Biology / trends
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy
  • Neovascularization, Pathologic / prevention & control*
  • Vinca Alkaloids / pharmacology
  • Vinca Alkaloids / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Vinca Alkaloids